Medtronic Inc. (NYSE:MDT) said Friday that the Food & Drug Administration approved a catheter-based therapy that uses freezing temperatures to combat atrial fibrillation.
The Fridley, Minn.-based medical device giant touts the Arctic Front system as the first FDA-approved technology to kill the diseased heart tissue that causes arrhythmia by zapping it with freezing temperatures.